Spyre Therapeutics, Inc.(SYRE)Earnings Date, History & Expected Move
Next report date, beat rate and options-implied move
SYRE is scheduled to report on Nov 5, 2026, usually after the market closes. Analysts expect EPS of -$0.83.
EPS: Actual vs Estimate
Reported EPS against the consensus estimate, last 12 quarters.
Green beat or met, red missed, amber sources differ.
Stock Reaction After Earnings
Close-to-close move in the first session that reflected each report.
Dashed lines mark the average actual move (±5.6%).
Did the stock rise after good news?
The next-day move after each of its last 6 EPS beats and 5 misses.
In plain words: it beat expectations 6 times, but the stock still fell 2 of those 6 times.
- May '26Missed▲ +2.7%
- Feb '26Beat▲ +14.3%
- Nov '25Beat▼ -0.6%
- Aug '25Beat▼ -5.4%
- May '25Beat▲ +9.6%
- Feb '25Beat▲ +7.2%
- Nov '24Missed▲ +5.0%
- Aug '24Beat▲ +2.9%
- May '24Missed▲ +4.9%
- Feb '24Missed▲ +9.0%
- Nov '23Missed▲ +0.2%
Clear beats and misses with a known reaction only. What counts as a beat
Why did SYRE fall after beating earnings?
7 of SYRE's last 11 reactions went against the EPS result. What stands out in each:
SYRE beat EPS estimates in 6 quarters, and the stock still closed lower the next day 2 times.
- Nov 4, 2025EPS beat +79.7%stock -0.6% next day
- It had risen 43.4% in the 20 trading sessions before the report, so good news may already have been priced in.
- It opened 1.7% higher, but sellers took over and it closed -0.6%.
- Aug 5, 2025EPS beat +31.0%stock -5.4% next day
- It had risen 8.1% in the 20 trading sessions before the report, so good news may already have been priced in.
Rose despite an EPS miss (5 of 5)
- May 5, 2026EPS missed -13.8%stock +2.7% next day
- It had already fallen 3.9% in the final week before the report, so weak results may have been expected.
- It opened 2.2% higher as soon as trading resumed.
- Nov 7, 2024EPS missed -58.1%stock +5.0% next day
Nothing in the price and estimate numbers we track stands out for this one. Guidance and management comments are not part of our data.
- May 9, 2024EPS missed -11.1%stock +4.9% next day
- It had already fallen 8.8% in the 20 trading sessions before the report, so weak results may have been expected.
- It opened 9.8% higher as soon as trading resumed.
- Feb 29, 2024EPS missed -388.0%stock +9.0% next day
- It opened 10.0% higher as soon as trading resumed.
- Nov 9, 2023EPS missed -1011.9%stock +0.2% next day
- It had already fallen 20.2% in the 20 trading sessions before the report, so weak results may have been expected.
Patterns in estimates and prices, not confirmed causes: how we read them.
Was SYRE's earnings move already priced in?
SYRE's move in the month before each of its last 11 reports, against what it did after.
How the run-up is measured (a move of 5% or more counts as large).
Before vs after each report
Grey: the month before each of the last 11 reports. Green or red: the day after.
Past reports only. How the run-up is measured
Does SYRE hold its opening gap after earnings?
SYRE's opening move after each report and where it closed that day.
In 9 reports SYRE opened at least 1% away from the previous close. It gave back half or more of that gap by the close 3 of 9 times (33%), and fully reversed 3 times. Gaps up faded 1 of 7; gaps down recovered 2 of 2.
- May 5, 2026HeldOpened +2.2%, closed +2.7%
- Nov 4, 2025ReversedOpened +1.7%, closed -0.6%
- May 8, 2025HeldOpened +5.3%, closed +9.6%
- Feb 27, 2025HeldOpened +1.7%, closed +7.2%
- Nov 7, 2024ReversedOpened -4.8%, closed +5.0%
- Aug 7, 2024HeldOpened +3.6%, closed +2.9%
- May 9, 2024HeldOpened +9.8%, closed +4.9%
- Feb 29, 2024HeldOpened +10.0%, closed +9.0%
SYRE earnings history
Last 12 reported quarters with the stock's reaction.
Swipe sideways to see every column →
| Report date | Time | EPS est. | EPS actual | Surprise | 1-day move | 3-day move |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | After close | -$0.75 | -$0.36 | +52.0% | — | — |
| May 5, 2026 | Before open | -$0.65 | -$0.74 | -13.8% | +2.72% | +5.74% |
| Feb 19, 2026 | After close | -$0.80 | -$0.74 | +7.5% | +14.28% | +14.92% |
| Nov 4, 2025 | After close | -$0.74 | -$0.15 | +79.7% | -0.57% | -2.00% |
| Aug 5, 2025 | After close | -$0.71 | -$0.49 | +31.0% | -5.39% | -10.14% |
| May 8, 2025 | After close | -$0.84 | -$0.60 | +28.6% | +9.64% | +14.70% |
| Feb 27, 2025 | After close | -$0.94 | -$0.81 | +13.8% | +7.24% | -0.82% |
| Nov 7, 2024 | After close | -$0.86 | -$1.36 | -58.1% | +5.00% | -4.96% |
| Aug 7, 2024 | After close | -$0.91 | -$0.86 | +5.5% | +2.85% | -0.98% |
| May 9, 2024 | After close | -$1.08 | -$1.20 | -11.1% | +4.94% | +11.65% |
| Feb 29, 2024 | After close | -$0.83 | -$4.05 | -388.0% | +8.97% | +37.21% |
| Nov 9, 2023 | After close | -$0.84 | -$9.34 | -1011.9% | +0.21% | +13.52% |
Consensus for the next report: EPS -$0.83, revenue $0.00.
SYRE Earnings FAQ
Answers computed from Spyre Therapeutics, Inc.'s reported history
SYRE is scheduled to report on Nov 5, 2026, usually after the market closes. Analysts expect EPS of -$0.83.
Over the last 12 quarters with a usable EPS surprise, SYRE beat the consensus estimate 7 times (58%), missed 5 and landed in line 0.
Across its last 11 quarters with a measured reaction, SYRE moved an average of ±5.6% in the first session after reporting. It closed higher 82% of the time; the largest gain was 14.3% and the largest drop -5.4%.
SYRE fell in the first session after 2 of its last 6 EPS beats (33%). A beat that was already priced in, or weaker guidance, can send a stock lower.
Across its last 11 quarters with price data, SYRE moved an average of +7.9% in the 20 trading sessions before reporting and was higher in 55% of them. After a run-up of 3% or more (6 quarters), it fell the next day 33% of the time, averaging +4.2%. After a drop of 3% or more (5 quarters), it rose the next day 100% of the time, averaging +5.0%. This describes past reports; it is not a forecast.
In 9 reports SYRE opened at least 1% away from the previous close. It gave back half or more of that gap by the close 3 of 9 times (33%), and fully reversed 3 times. A fade means the opening move was partly undone during the first session.
How we calculate these numbers · SYRE: 12 reported quarters, latest Aug 4, 2026. Information only, not investment advice.
Looking for more on SYRE?
Price charts, forecast, fundamentals and risk pages for SYRE are not on Tickzen yet. You can run a full stock analysis now.
Run the SYRE Stock AnalyzerLatest TickZen Insights
HSBC Q3 2026 Earnings Preview: Is the $46bn NII Guide Too Low?By Vishal Jadaun
Coca-Cola (KO) Q3 2026 Earnings Preview: Can Growth Justify Its Valuation?By Vishal Jadaun
Welltower Q3 2026 Earnings Preview: Can 20% Senior Housing Growth Last?By Vishal Jadaun